Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
6,367
archived clinical trials in
High Blood Pressure (Hypertension)

An Extension Study to Evaluate the Long Term Safety, Tolerability and Efficacy of Aliskiren Compared to Enalapril in Pediatric Hypertensive Patients 6-17 Years of Age
A Multicenter, Double-blind, Randomized, 52-week, Extension Study to Evaluate the Long Term Safety, Tolerability and Efficacy of Aliskiren Compared to Enalapril in Pediatric Hypertensive Patients 6-17 Years of Age
Status: Enrolling
Updated:  2/8/2016
Novartis Investigative Site
mi
from
Little Rock, AR
An Extension Study to Evaluate the Long Term Safety, Tolerability and Efficacy of Aliskiren Compared to Enalapril in Pediatric Hypertensive Patients 6-17 Years of Age
A Multicenter, Double-blind, Randomized, 52-week, Extension Study to Evaluate the Long Term Safety, Tolerability and Efficacy of Aliskiren Compared to Enalapril in Pediatric Hypertensive Patients 6-17 Years of Age
Status: Enrolling
Updated: 2/8/2016
Novartis Investigative Site
mi
from
Little Rock, AR
Click here to add this to my saved trials
An Extension Study to Evaluate the Long Term Safety, Tolerability and Efficacy of Aliskiren Compared to Enalapril in Pediatric Hypertensive Patients 6-17 Years of Age
A Multicenter, Double-blind, Randomized, 52-week, Extension Study to Evaluate the Long Term Safety, Tolerability and Efficacy of Aliskiren Compared to Enalapril in Pediatric Hypertensive Patients 6-17 Years of Age
Status: Enrolling
Updated:  2/8/2016
Novartis Investigative site
mi
from
Los Angeles, CA
An Extension Study to Evaluate the Long Term Safety, Tolerability and Efficacy of Aliskiren Compared to Enalapril in Pediatric Hypertensive Patients 6-17 Years of Age
A Multicenter, Double-blind, Randomized, 52-week, Extension Study to Evaluate the Long Term Safety, Tolerability and Efficacy of Aliskiren Compared to Enalapril in Pediatric Hypertensive Patients 6-17 Years of Age
Status: Enrolling
Updated: 2/8/2016
Novartis Investigative site
mi
from
Los Angeles, CA
Click here to add this to my saved trials
An Extension Study to Evaluate the Long Term Safety, Tolerability and Efficacy of Aliskiren Compared to Enalapril in Pediatric Hypertensive Patients 6-17 Years of Age
A Multicenter, Double-blind, Randomized, 52-week, Extension Study to Evaluate the Long Term Safety, Tolerability and Efficacy of Aliskiren Compared to Enalapril in Pediatric Hypertensive Patients 6-17 Years of Age
Status: Enrolling
Updated:  2/8/2016
Novartis Investigative Site
mi
from
Dalton, GA
An Extension Study to Evaluate the Long Term Safety, Tolerability and Efficacy of Aliskiren Compared to Enalapril in Pediatric Hypertensive Patients 6-17 Years of Age
A Multicenter, Double-blind, Randomized, 52-week, Extension Study to Evaluate the Long Term Safety, Tolerability and Efficacy of Aliskiren Compared to Enalapril in Pediatric Hypertensive Patients 6-17 Years of Age
Status: Enrolling
Updated: 2/8/2016
Novartis Investigative Site
mi
from
Dalton, GA
Click here to add this to my saved trials
An Extension Study to Evaluate the Long Term Safety, Tolerability and Efficacy of Aliskiren Compared to Enalapril in Pediatric Hypertensive Patients 6-17 Years of Age
A Multicenter, Double-blind, Randomized, 52-week, Extension Study to Evaluate the Long Term Safety, Tolerability and Efficacy of Aliskiren Compared to Enalapril in Pediatric Hypertensive Patients 6-17 Years of Age
Status: Enrolling
Updated:  2/8/2016
Novartis Investigative Site
mi
from
Lewiston, ID
An Extension Study to Evaluate the Long Term Safety, Tolerability and Efficacy of Aliskiren Compared to Enalapril in Pediatric Hypertensive Patients 6-17 Years of Age
A Multicenter, Double-blind, Randomized, 52-week, Extension Study to Evaluate the Long Term Safety, Tolerability and Efficacy of Aliskiren Compared to Enalapril in Pediatric Hypertensive Patients 6-17 Years of Age
Status: Enrolling
Updated: 2/8/2016
Novartis Investigative Site
mi
from
Lewiston, ID
Click here to add this to my saved trials
An Extension Study to Evaluate the Long Term Safety, Tolerability and Efficacy of Aliskiren Compared to Enalapril in Pediatric Hypertensive Patients 6-17 Years of Age
A Multicenter, Double-blind, Randomized, 52-week, Extension Study to Evaluate the Long Term Safety, Tolerability and Efficacy of Aliskiren Compared to Enalapril in Pediatric Hypertensive Patients 6-17 Years of Age
Status: Enrolling
Updated:  2/8/2016
Novartis Investigative Site
mi
from
Park Ridge, IL
An Extension Study to Evaluate the Long Term Safety, Tolerability and Efficacy of Aliskiren Compared to Enalapril in Pediatric Hypertensive Patients 6-17 Years of Age
A Multicenter, Double-blind, Randomized, 52-week, Extension Study to Evaluate the Long Term Safety, Tolerability and Efficacy of Aliskiren Compared to Enalapril in Pediatric Hypertensive Patients 6-17 Years of Age
Status: Enrolling
Updated: 2/8/2016
Novartis Investigative Site
mi
from
Park Ridge, IL
Click here to add this to my saved trials
An Extension Study to Evaluate the Long Term Safety, Tolerability and Efficacy of Aliskiren Compared to Enalapril in Pediatric Hypertensive Patients 6-17 Years of Age
A Multicenter, Double-blind, Randomized, 52-week, Extension Study to Evaluate the Long Term Safety, Tolerability and Efficacy of Aliskiren Compared to Enalapril in Pediatric Hypertensive Patients 6-17 Years of Age
Status: Enrolling
Updated:  2/8/2016
Novartis Investigative Site
mi
from
Louisville, KY
An Extension Study to Evaluate the Long Term Safety, Tolerability and Efficacy of Aliskiren Compared to Enalapril in Pediatric Hypertensive Patients 6-17 Years of Age
A Multicenter, Double-blind, Randomized, 52-week, Extension Study to Evaluate the Long Term Safety, Tolerability and Efficacy of Aliskiren Compared to Enalapril in Pediatric Hypertensive Patients 6-17 Years of Age
Status: Enrolling
Updated: 2/8/2016
Novartis Investigative Site
mi
from
Louisville, KY
Click here to add this to my saved trials
An Extension Study to Evaluate the Long Term Safety, Tolerability and Efficacy of Aliskiren Compared to Enalapril in Pediatric Hypertensive Patients 6-17 Years of Age
A Multicenter, Double-blind, Randomized, 52-week, Extension Study to Evaluate the Long Term Safety, Tolerability and Efficacy of Aliskiren Compared to Enalapril in Pediatric Hypertensive Patients 6-17 Years of Age
Status: Enrolling
Updated:  2/8/2016
Novartis Investigative Site
mi
from
Hattiesburg, MS
An Extension Study to Evaluate the Long Term Safety, Tolerability and Efficacy of Aliskiren Compared to Enalapril in Pediatric Hypertensive Patients 6-17 Years of Age
A Multicenter, Double-blind, Randomized, 52-week, Extension Study to Evaluate the Long Term Safety, Tolerability and Efficacy of Aliskiren Compared to Enalapril in Pediatric Hypertensive Patients 6-17 Years of Age
Status: Enrolling
Updated: 2/8/2016
Novartis Investigative Site
mi
from
Hattiesburg, MS
Click here to add this to my saved trials
An Extension Study to Evaluate the Long Term Safety, Tolerability and Efficacy of Aliskiren Compared to Enalapril in Pediatric Hypertensive Patients 6-17 Years of Age
A Multicenter, Double-blind, Randomized, 52-week, Extension Study to Evaluate the Long Term Safety, Tolerability and Efficacy of Aliskiren Compared to Enalapril in Pediatric Hypertensive Patients 6-17 Years of Age
Status: Enrolling
Updated:  2/8/2016
Novartis Investigative Site
mi
from
Jackson, MS
An Extension Study to Evaluate the Long Term Safety, Tolerability and Efficacy of Aliskiren Compared to Enalapril in Pediatric Hypertensive Patients 6-17 Years of Age
A Multicenter, Double-blind, Randomized, 52-week, Extension Study to Evaluate the Long Term Safety, Tolerability and Efficacy of Aliskiren Compared to Enalapril in Pediatric Hypertensive Patients 6-17 Years of Age
Status: Enrolling
Updated: 2/8/2016
Novartis Investigative Site
mi
from
Jackson, MS
Click here to add this to my saved trials
An Extension Study to Evaluate the Long Term Safety, Tolerability and Efficacy of Aliskiren Compared to Enalapril in Pediatric Hypertensive Patients 6-17 Years of Age
A Multicenter, Double-blind, Randomized, 52-week, Extension Study to Evaluate the Long Term Safety, Tolerability and Efficacy of Aliskiren Compared to Enalapril in Pediatric Hypertensive Patients 6-17 Years of Age
Status: Enrolling
Updated:  2/8/2016
Novartis Investigative Site
mi
from
Jackson, MS
An Extension Study to Evaluate the Long Term Safety, Tolerability and Efficacy of Aliskiren Compared to Enalapril in Pediatric Hypertensive Patients 6-17 Years of Age
A Multicenter, Double-blind, Randomized, 52-week, Extension Study to Evaluate the Long Term Safety, Tolerability and Efficacy of Aliskiren Compared to Enalapril in Pediatric Hypertensive Patients 6-17 Years of Age
Status: Enrolling
Updated: 2/8/2016
Novartis Investigative Site
mi
from
Jackson, MS
Click here to add this to my saved trials
An Extension Study to Evaluate the Long Term Safety, Tolerability and Efficacy of Aliskiren Compared to Enalapril in Pediatric Hypertensive Patients 6-17 Years of Age
A Multicenter, Double-blind, Randomized, 52-week, Extension Study to Evaluate the Long Term Safety, Tolerability and Efficacy of Aliskiren Compared to Enalapril in Pediatric Hypertensive Patients 6-17 Years of Age
Status: Enrolling
Updated:  2/8/2016
Novartis
mi
from
New York, NY
An Extension Study to Evaluate the Long Term Safety, Tolerability and Efficacy of Aliskiren Compared to Enalapril in Pediatric Hypertensive Patients 6-17 Years of Age
A Multicenter, Double-blind, Randomized, 52-week, Extension Study to Evaluate the Long Term Safety, Tolerability and Efficacy of Aliskiren Compared to Enalapril in Pediatric Hypertensive Patients 6-17 Years of Age
Status: Enrolling
Updated: 2/8/2016
Novartis
mi
from
New York, NY
Click here to add this to my saved trials
An Extension Study to Evaluate the Long Term Safety, Tolerability and Efficacy of Aliskiren Compared to Enalapril in Pediatric Hypertensive Patients 6-17 Years of Age
A Multicenter, Double-blind, Randomized, 52-week, Extension Study to Evaluate the Long Term Safety, Tolerability and Efficacy of Aliskiren Compared to Enalapril in Pediatric Hypertensive Patients 6-17 Years of Age
Status: Enrolling
Updated:  2/8/2016
Novartis Investigative Site
mi
from
Columbus, OH
An Extension Study to Evaluate the Long Term Safety, Tolerability and Efficacy of Aliskiren Compared to Enalapril in Pediatric Hypertensive Patients 6-17 Years of Age
A Multicenter, Double-blind, Randomized, 52-week, Extension Study to Evaluate the Long Term Safety, Tolerability and Efficacy of Aliskiren Compared to Enalapril in Pediatric Hypertensive Patients 6-17 Years of Age
Status: Enrolling
Updated: 2/8/2016
Novartis Investigative Site
mi
from
Columbus, OH
Click here to add this to my saved trials
An Extension Study to Evaluate the Long Term Safety, Tolerability and Efficacy of Aliskiren Compared to Enalapril in Pediatric Hypertensive Patients 6-17 Years of Age
A Multicenter, Double-blind, Randomized, 52-week, Extension Study to Evaluate the Long Term Safety, Tolerability and Efficacy of Aliskiren Compared to Enalapril in Pediatric Hypertensive Patients 6-17 Years of Age
Status: Enrolling
Updated:  2/8/2016
Novartis Investigative Site
mi
from
Toledo, OH
An Extension Study to Evaluate the Long Term Safety, Tolerability and Efficacy of Aliskiren Compared to Enalapril in Pediatric Hypertensive Patients 6-17 Years of Age
A Multicenter, Double-blind, Randomized, 52-week, Extension Study to Evaluate the Long Term Safety, Tolerability and Efficacy of Aliskiren Compared to Enalapril in Pediatric Hypertensive Patients 6-17 Years of Age
Status: Enrolling
Updated: 2/8/2016
Novartis Investigative Site
mi
from
Toledo, OH
Click here to add this to my saved trials
An Extension Study to Evaluate the Long Term Safety, Tolerability and Efficacy of Aliskiren Compared to Enalapril in Pediatric Hypertensive Patients 6-17 Years of Age
A Multicenter, Double-blind, Randomized, 52-week, Extension Study to Evaluate the Long Term Safety, Tolerability and Efficacy of Aliskiren Compared to Enalapril in Pediatric Hypertensive Patients 6-17 Years of Age
Status: Enrolling
Updated:  2/8/2016
Novartis
mi
from
Portland, OR
An Extension Study to Evaluate the Long Term Safety, Tolerability and Efficacy of Aliskiren Compared to Enalapril in Pediatric Hypertensive Patients 6-17 Years of Age
A Multicenter, Double-blind, Randomized, 52-week, Extension Study to Evaluate the Long Term Safety, Tolerability and Efficacy of Aliskiren Compared to Enalapril in Pediatric Hypertensive Patients 6-17 Years of Age
Status: Enrolling
Updated: 2/8/2016
Novartis
mi
from
Portland, OR
Click here to add this to my saved trials
An Extension Study to Evaluate the Long Term Safety, Tolerability and Efficacy of Aliskiren Compared to Enalapril in Pediatric Hypertensive Patients 6-17 Years of Age
A Multicenter, Double-blind, Randomized, 52-week, Extension Study to Evaluate the Long Term Safety, Tolerability and Efficacy of Aliskiren Compared to Enalapril in Pediatric Hypertensive Patients 6-17 Years of Age
Status: Enrolling
Updated:  2/8/2016
Novartis
mi
from
Portland, OR
An Extension Study to Evaluate the Long Term Safety, Tolerability and Efficacy of Aliskiren Compared to Enalapril in Pediatric Hypertensive Patients 6-17 Years of Age
A Multicenter, Double-blind, Randomized, 52-week, Extension Study to Evaluate the Long Term Safety, Tolerability and Efficacy of Aliskiren Compared to Enalapril in Pediatric Hypertensive Patients 6-17 Years of Age
Status: Enrolling
Updated: 2/8/2016
Novartis
mi
from
Portland, OR
Click here to add this to my saved trials
An Extension Study to Evaluate the Long Term Safety, Tolerability and Efficacy of Aliskiren Compared to Enalapril in Pediatric Hypertensive Patients 6-17 Years of Age
A Multicenter, Double-blind, Randomized, 52-week, Extension Study to Evaluate the Long Term Safety, Tolerability and Efficacy of Aliskiren Compared to Enalapril in Pediatric Hypertensive Patients 6-17 Years of Age
Status: Enrolling
Updated:  2/8/2016
Novartis Investigational Site
mi
from
Charleston, SC
An Extension Study to Evaluate the Long Term Safety, Tolerability and Efficacy of Aliskiren Compared to Enalapril in Pediatric Hypertensive Patients 6-17 Years of Age
A Multicenter, Double-blind, Randomized, 52-week, Extension Study to Evaluate the Long Term Safety, Tolerability and Efficacy of Aliskiren Compared to Enalapril in Pediatric Hypertensive Patients 6-17 Years of Age
Status: Enrolling
Updated: 2/8/2016
Novartis Investigational Site
mi
from
Charleston, SC
Click here to add this to my saved trials
An Extension Study to Evaluate the Long Term Safety, Tolerability and Efficacy of Aliskiren Compared to Enalapril in Pediatric Hypertensive Patients 6-17 Years of Age
A Multicenter, Double-blind, Randomized, 52-week, Extension Study to Evaluate the Long Term Safety, Tolerability and Efficacy of Aliskiren Compared to Enalapril in Pediatric Hypertensive Patients 6-17 Years of Age
Status: Enrolling
Updated:  2/8/2016
Novartis Investigative Site
mi
from
Amarillo, TX
An Extension Study to Evaluate the Long Term Safety, Tolerability and Efficacy of Aliskiren Compared to Enalapril in Pediatric Hypertensive Patients 6-17 Years of Age
A Multicenter, Double-blind, Randomized, 52-week, Extension Study to Evaluate the Long Term Safety, Tolerability and Efficacy of Aliskiren Compared to Enalapril in Pediatric Hypertensive Patients 6-17 Years of Age
Status: Enrolling
Updated: 2/8/2016
Novartis Investigative Site
mi
from
Amarillo, TX
Click here to add this to my saved trials
An Extension Study to Evaluate the Long Term Safety, Tolerability and Efficacy of Aliskiren Compared to Enalapril in Pediatric Hypertensive Patients 6-17 Years of Age
A Multicenter, Double-blind, Randomized, 52-week, Extension Study to Evaluate the Long Term Safety, Tolerability and Efficacy of Aliskiren Compared to Enalapril in Pediatric Hypertensive Patients 6-17 Years of Age
Status: Enrolling
Updated:  2/8/2016
Novartis Investigative Site
mi
from
Charleston, WV
An Extension Study to Evaluate the Long Term Safety, Tolerability and Efficacy of Aliskiren Compared to Enalapril in Pediatric Hypertensive Patients 6-17 Years of Age
A Multicenter, Double-blind, Randomized, 52-week, Extension Study to Evaluate the Long Term Safety, Tolerability and Efficacy of Aliskiren Compared to Enalapril in Pediatric Hypertensive Patients 6-17 Years of Age
Status: Enrolling
Updated: 2/8/2016
Novartis Investigative Site
mi
from
Charleston, WV
Click here to add this to my saved trials
An Extension Study to Evaluate the Long Term Safety, Tolerability and Efficacy of Aliskiren Compared to Enalapril in Pediatric Hypertensive Patients 6-17 Years of Age
A Multicenter, Double-blind, Randomized, 52-week, Extension Study to Evaluate the Long Term Safety, Tolerability and Efficacy of Aliskiren Compared to Enalapril in Pediatric Hypertensive Patients 6-17 Years of Age
Status: Enrolling
Updated:  2/8/2016
Novartis Investigative Site
mi
from
Guatemala City,
An Extension Study to Evaluate the Long Term Safety, Tolerability and Efficacy of Aliskiren Compared to Enalapril in Pediatric Hypertensive Patients 6-17 Years of Age
A Multicenter, Double-blind, Randomized, 52-week, Extension Study to Evaluate the Long Term Safety, Tolerability and Efficacy of Aliskiren Compared to Enalapril in Pediatric Hypertensive Patients 6-17 Years of Age
Status: Enrolling
Updated: 2/8/2016
Novartis Investigative Site
mi
from
Guatemala City,
Click here to add this to my saved trials
A Proof of Concept Study of Electrical Discharge Produced Nitric Oxide for Inhalation
A Proof of Concept Study of Electrical Discharge Produced Nitric Oxide for Inhalation
Status: Enrolling
Updated:  2/8/2016
Massachusetts General Hospital
mi
from
Boston, MA
A Proof of Concept Study of Electrical Discharge Produced Nitric Oxide for Inhalation
A Proof of Concept Study of Electrical Discharge Produced Nitric Oxide for Inhalation
Status: Enrolling
Updated: 2/8/2016
Massachusetts General Hospital
mi
from
Boston, MA
Click here to add this to my saved trials
Assessing Blood Pressure Remotely in Childhood Cancer Survivors
Feasibility of Assessing Blood Pressure Remotely in Childhood Cancer Survivors (Pilot Study-Survivor)
Status: Enrolling
Updated:  2/12/2016
St. Jude Children's Research Hospital
mi
from
Memphis, TN
Assessing Blood Pressure Remotely in Childhood Cancer Survivors
Feasibility of Assessing Blood Pressure Remotely in Childhood Cancer Survivors (Pilot Study-Survivor)
Status: Enrolling
Updated: 2/12/2016
St. Jude Children's Research Hospital
mi
from
Memphis, TN
Click here to add this to my saved trials
Acute Effects of Inorganic Nitrite on Cardiovascular Hemodynamics in Heart Failure With Preserved Ejection Fraction
Acute Effects of Inorganic Nitrite on Cardiovascular Hemodynamics in Heart Failure With Preserved Ejection Fraction
Status: Enrolling
Updated:  2/15/2016
Mayo Clinic Rochester
mi
from
Rochester, MN
Acute Effects of Inorganic Nitrite on Cardiovascular Hemodynamics in Heart Failure With Preserved Ejection Fraction
Acute Effects of Inorganic Nitrite on Cardiovascular Hemodynamics in Heart Failure With Preserved Ejection Fraction
Status: Enrolling
Updated: 2/15/2016
Mayo Clinic Rochester
mi
from
Rochester, MN
Click here to add this to my saved trials
Early Identification and Action in CKD
Early Identification and Action in CKD
Status: Enrolling
Updated:  2/15/2016
Geisinger Health System
mi
from
Danville, PA
Early Identification and Action in CKD
Early Identification and Action in CKD
Status: Enrolling
Updated: 2/15/2016
Geisinger Health System
mi
from
Danville, PA
Click here to add this to my saved trials
Efficacy and Safety of Cobiprostone in Patients With Portal Hypertension
A Randomized, Placebo-controlled, Double-blinded Study of the Efficacy and Safety of Cobiprostone in Patients With Portal Hypertension
Status: Enrolling
Updated:  2/16/2016
University of Texas Southwestern Medical Center
mi
from
Dallas, TX
Efficacy and Safety of Cobiprostone in Patients With Portal Hypertension
A Randomized, Placebo-controlled, Double-blinded Study of the Efficacy and Safety of Cobiprostone in Patients With Portal Hypertension
Status: Enrolling
Updated: 2/16/2016
University of Texas Southwestern Medical Center
mi
from
Dallas, TX
Click here to add this to my saved trials
Imatinib (QTI571) in Pulmonary Arterial Hypertension
A 24-week Randomized Placebo-controlled, Double-blind Multi-center Clinical Trial Evaluating the Efficacy and Safety of Oral QTI571 as an add-on Therapy in the Treatment of Severe Pulmonary Arterial Hypertension: Imatinib in Pulmonary Arterial Hypertension, a Randomized, Efficacy Study (IMPRES)
Status: Enrolling
Updated:  2/16/2016
Novartis Investigator Site
mi
from
Birmingham, AL
Imatinib (QTI571) in Pulmonary Arterial Hypertension
A 24-week Randomized Placebo-controlled, Double-blind Multi-center Clinical Trial Evaluating the Efficacy and Safety of Oral QTI571 as an add-on Therapy in the Treatment of Severe Pulmonary Arterial Hypertension: Imatinib in Pulmonary Arterial Hypertension, a Randomized, Efficacy Study (IMPRES)
Status: Enrolling
Updated: 2/16/2016
Novartis Investigator Site
mi
from
Birmingham, AL
Click here to add this to my saved trials
Imatinib (QTI571) in Pulmonary Arterial Hypertension
A 24-week Randomized Placebo-controlled, Double-blind Multi-center Clinical Trial Evaluating the Efficacy and Safety of Oral QTI571 as an add-on Therapy in the Treatment of Severe Pulmonary Arterial Hypertension: Imatinib in Pulmonary Arterial Hypertension, a Randomized, Efficacy Study (IMPRES)
Status: Enrolling
Updated:  2/16/2016
Novartis Investigative Site
mi
from
Phoenix, AZ
Imatinib (QTI571) in Pulmonary Arterial Hypertension
A 24-week Randomized Placebo-controlled, Double-blind Multi-center Clinical Trial Evaluating the Efficacy and Safety of Oral QTI571 as an add-on Therapy in the Treatment of Severe Pulmonary Arterial Hypertension: Imatinib in Pulmonary Arterial Hypertension, a Randomized, Efficacy Study (IMPRES)
Status: Enrolling
Updated: 2/16/2016
Novartis Investigative Site
mi
from
Phoenix, AZ
Click here to add this to my saved trials
Imatinib (QTI571) in Pulmonary Arterial Hypertension
A 24-week Randomized Placebo-controlled, Double-blind Multi-center Clinical Trial Evaluating the Efficacy and Safety of Oral QTI571 as an add-on Therapy in the Treatment of Severe Pulmonary Arterial Hypertension: Imatinib in Pulmonary Arterial Hypertension, a Randomized, Efficacy Study (IMPRES)
Status: Enrolling
Updated:  2/16/2016
Novartis Investigative site
mi
from
Los Angeles, CA
Imatinib (QTI571) in Pulmonary Arterial Hypertension
A 24-week Randomized Placebo-controlled, Double-blind Multi-center Clinical Trial Evaluating the Efficacy and Safety of Oral QTI571 as an add-on Therapy in the Treatment of Severe Pulmonary Arterial Hypertension: Imatinib in Pulmonary Arterial Hypertension, a Randomized, Efficacy Study (IMPRES)
Status: Enrolling
Updated: 2/16/2016
Novartis Investigative site
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Imatinib (QTI571) in Pulmonary Arterial Hypertension
A 24-week Randomized Placebo-controlled, Double-blind Multi-center Clinical Trial Evaluating the Efficacy and Safety of Oral QTI571 as an add-on Therapy in the Treatment of Severe Pulmonary Arterial Hypertension: Imatinib in Pulmonary Arterial Hypertension, a Randomized, Efficacy Study (IMPRES)
Status: Enrolling
Updated:  2/16/2016
Novartis Investigative Site
mi
from
San Francisco, CA
Imatinib (QTI571) in Pulmonary Arterial Hypertension
A 24-week Randomized Placebo-controlled, Double-blind Multi-center Clinical Trial Evaluating the Efficacy and Safety of Oral QTI571 as an add-on Therapy in the Treatment of Severe Pulmonary Arterial Hypertension: Imatinib in Pulmonary Arterial Hypertension, a Randomized, Efficacy Study (IMPRES)
Status: Enrolling
Updated: 2/16/2016
Novartis Investigative Site
mi
from
San Francisco, CA
Click here to add this to my saved trials
Imatinib (QTI571) in Pulmonary Arterial Hypertension
A 24-week Randomized Placebo-controlled, Double-blind Multi-center Clinical Trial Evaluating the Efficacy and Safety of Oral QTI571 as an add-on Therapy in the Treatment of Severe Pulmonary Arterial Hypertension: Imatinib in Pulmonary Arterial Hypertension, a Randomized, Efficacy Study (IMPRES)
Status: Enrolling
Updated:  2/16/2016
Novartis Investigative site
mi
from
Aurora, CO
Imatinib (QTI571) in Pulmonary Arterial Hypertension
A 24-week Randomized Placebo-controlled, Double-blind Multi-center Clinical Trial Evaluating the Efficacy and Safety of Oral QTI571 as an add-on Therapy in the Treatment of Severe Pulmonary Arterial Hypertension: Imatinib in Pulmonary Arterial Hypertension, a Randomized, Efficacy Study (IMPRES)
Status: Enrolling
Updated: 2/16/2016
Novartis Investigative site
mi
from
Aurora, CO
Click here to add this to my saved trials
Imatinib (QTI571) in Pulmonary Arterial Hypertension
A 24-week Randomized Placebo-controlled, Double-blind Multi-center Clinical Trial Evaluating the Efficacy and Safety of Oral QTI571 as an add-on Therapy in the Treatment of Severe Pulmonary Arterial Hypertension: Imatinib in Pulmonary Arterial Hypertension, a Randomized, Efficacy Study (IMPRES)
Status: Enrolling
Updated:  2/16/2016
Novartis Investigator Site
mi
from
Clearwater, FL
Imatinib (QTI571) in Pulmonary Arterial Hypertension
A 24-week Randomized Placebo-controlled, Double-blind Multi-center Clinical Trial Evaluating the Efficacy and Safety of Oral QTI571 as an add-on Therapy in the Treatment of Severe Pulmonary Arterial Hypertension: Imatinib in Pulmonary Arterial Hypertension, a Randomized, Efficacy Study (IMPRES)
Status: Enrolling
Updated: 2/16/2016
Novartis Investigator Site
mi
from
Clearwater, FL
Click here to add this to my saved trials
Imatinib (QTI571) in Pulmonary Arterial Hypertension
A 24-week Randomized Placebo-controlled, Double-blind Multi-center Clinical Trial Evaluating the Efficacy and Safety of Oral QTI571 as an add-on Therapy in the Treatment of Severe Pulmonary Arterial Hypertension: Imatinib in Pulmonary Arterial Hypertension, a Randomized, Efficacy Study (IMPRES)
Status: Enrolling
Updated:  2/16/2016
Novartis Investigative Site
mi
from
Miami Beach, FL
Imatinib (QTI571) in Pulmonary Arterial Hypertension
A 24-week Randomized Placebo-controlled, Double-blind Multi-center Clinical Trial Evaluating the Efficacy and Safety of Oral QTI571 as an add-on Therapy in the Treatment of Severe Pulmonary Arterial Hypertension: Imatinib in Pulmonary Arterial Hypertension, a Randomized, Efficacy Study (IMPRES)
Status: Enrolling
Updated: 2/16/2016
Novartis Investigative Site
mi
from
Miami Beach, FL
Click here to add this to my saved trials
Imatinib (QTI571) in Pulmonary Arterial Hypertension
A 24-week Randomized Placebo-controlled, Double-blind Multi-center Clinical Trial Evaluating the Efficacy and Safety of Oral QTI571 as an add-on Therapy in the Treatment of Severe Pulmonary Arterial Hypertension: Imatinib in Pulmonary Arterial Hypertension, a Randomized, Efficacy Study (IMPRES)
Status: Enrolling
Updated:  2/16/2016
Novartis Investigative Site
mi
from
Weston, FL
Imatinib (QTI571) in Pulmonary Arterial Hypertension
A 24-week Randomized Placebo-controlled, Double-blind Multi-center Clinical Trial Evaluating the Efficacy and Safety of Oral QTI571 as an add-on Therapy in the Treatment of Severe Pulmonary Arterial Hypertension: Imatinib in Pulmonary Arterial Hypertension, a Randomized, Efficacy Study (IMPRES)
Status: Enrolling
Updated: 2/16/2016
Novartis Investigative Site
mi
from
Weston, FL
Click here to add this to my saved trials
Imatinib (QTI571) in Pulmonary Arterial Hypertension
A 24-week Randomized Placebo-controlled, Double-blind Multi-center Clinical Trial Evaluating the Efficacy and Safety of Oral QTI571 as an add-on Therapy in the Treatment of Severe Pulmonary Arterial Hypertension: Imatinib in Pulmonary Arterial Hypertension, a Randomized, Efficacy Study (IMPRES)
Status: Enrolling
Updated:  2/16/2016
Novartis Investigative Site
mi
from
Atlanta, GA
Imatinib (QTI571) in Pulmonary Arterial Hypertension
A 24-week Randomized Placebo-controlled, Double-blind Multi-center Clinical Trial Evaluating the Efficacy and Safety of Oral QTI571 as an add-on Therapy in the Treatment of Severe Pulmonary Arterial Hypertension: Imatinib in Pulmonary Arterial Hypertension, a Randomized, Efficacy Study (IMPRES)
Status: Enrolling
Updated: 2/16/2016
Novartis Investigative Site
mi
from
Atlanta, GA
Click here to add this to my saved trials
Imatinib (QTI571) in Pulmonary Arterial Hypertension
A 24-week Randomized Placebo-controlled, Double-blind Multi-center Clinical Trial Evaluating the Efficacy and Safety of Oral QTI571 as an add-on Therapy in the Treatment of Severe Pulmonary Arterial Hypertension: Imatinib in Pulmonary Arterial Hypertension, a Randomized, Efficacy Study (IMPRES)
Status: Enrolling
Updated:  2/16/2016
Novartis Investigator Site
mi
from
Chicago, IL
Imatinib (QTI571) in Pulmonary Arterial Hypertension
A 24-week Randomized Placebo-controlled, Double-blind Multi-center Clinical Trial Evaluating the Efficacy and Safety of Oral QTI571 as an add-on Therapy in the Treatment of Severe Pulmonary Arterial Hypertension: Imatinib in Pulmonary Arterial Hypertension, a Randomized, Efficacy Study (IMPRES)
Status: Enrolling
Updated: 2/16/2016
Novartis Investigator Site
mi
from
Chicago, IL
Click here to add this to my saved trials
Imatinib (QTI571) in Pulmonary Arterial Hypertension
A 24-week Randomized Placebo-controlled, Double-blind Multi-center Clinical Trial Evaluating the Efficacy and Safety of Oral QTI571 as an add-on Therapy in the Treatment of Severe Pulmonary Arterial Hypertension: Imatinib in Pulmonary Arterial Hypertension, a Randomized, Efficacy Study (IMPRES)
Status: Enrolling
Updated:  2/16/2016
Novartis
mi
from
Baltimore, MD
Imatinib (QTI571) in Pulmonary Arterial Hypertension
A 24-week Randomized Placebo-controlled, Double-blind Multi-center Clinical Trial Evaluating the Efficacy and Safety of Oral QTI571 as an add-on Therapy in the Treatment of Severe Pulmonary Arterial Hypertension: Imatinib in Pulmonary Arterial Hypertension, a Randomized, Efficacy Study (IMPRES)
Status: Enrolling
Updated: 2/16/2016
Novartis
mi
from
Baltimore, MD
Click here to add this to my saved trials
Imatinib (QTI571) in Pulmonary Arterial Hypertension
A 24-week Randomized Placebo-controlled, Double-blind Multi-center Clinical Trial Evaluating the Efficacy and Safety of Oral QTI571 as an add-on Therapy in the Treatment of Severe Pulmonary Arterial Hypertension: Imatinib in Pulmonary Arterial Hypertension, a Randomized, Efficacy Study (IMPRES)
Status: Enrolling
Updated:  2/16/2016
Novartis Investigative site
mi
from
Boston, MA
Imatinib (QTI571) in Pulmonary Arterial Hypertension
A 24-week Randomized Placebo-controlled, Double-blind Multi-center Clinical Trial Evaluating the Efficacy and Safety of Oral QTI571 as an add-on Therapy in the Treatment of Severe Pulmonary Arterial Hypertension: Imatinib in Pulmonary Arterial Hypertension, a Randomized, Efficacy Study (IMPRES)
Status: Enrolling
Updated: 2/16/2016
Novartis Investigative site
mi
from
Boston, MA
Click here to add this to my saved trials
Imatinib (QTI571) in Pulmonary Arterial Hypertension
A 24-week Randomized Placebo-controlled, Double-blind Multi-center Clinical Trial Evaluating the Efficacy and Safety of Oral QTI571 as an add-on Therapy in the Treatment of Severe Pulmonary Arterial Hypertension: Imatinib in Pulmonary Arterial Hypertension, a Randomized, Efficacy Study (IMPRES)
Status: Enrolling
Updated:  2/16/2016
Novartis Investigative Site
mi
from
Rochester, MN
Imatinib (QTI571) in Pulmonary Arterial Hypertension
A 24-week Randomized Placebo-controlled, Double-blind Multi-center Clinical Trial Evaluating the Efficacy and Safety of Oral QTI571 as an add-on Therapy in the Treatment of Severe Pulmonary Arterial Hypertension: Imatinib in Pulmonary Arterial Hypertension, a Randomized, Efficacy Study (IMPRES)
Status: Enrolling
Updated: 2/16/2016
Novartis Investigative Site
mi
from
Rochester, MN
Click here to add this to my saved trials
Imatinib (QTI571) in Pulmonary Arterial Hypertension
A 24-week Randomized Placebo-controlled, Double-blind Multi-center Clinical Trial Evaluating the Efficacy and Safety of Oral QTI571 as an add-on Therapy in the Treatment of Severe Pulmonary Arterial Hypertension: Imatinib in Pulmonary Arterial Hypertension, a Randomized, Efficacy Study (IMPRES)
Status: Enrolling
Updated:  2/16/2016
Novartis Investigative Site
mi
from
St. Louis, MO
Imatinib (QTI571) in Pulmonary Arterial Hypertension
A 24-week Randomized Placebo-controlled, Double-blind Multi-center Clinical Trial Evaluating the Efficacy and Safety of Oral QTI571 as an add-on Therapy in the Treatment of Severe Pulmonary Arterial Hypertension: Imatinib in Pulmonary Arterial Hypertension, a Randomized, Efficacy Study (IMPRES)
Status: Enrolling
Updated: 2/16/2016
Novartis Investigative Site
mi
from
St. Louis, MO
Click here to add this to my saved trials
Imatinib (QTI571) in Pulmonary Arterial Hypertension
A 24-week Randomized Placebo-controlled, Double-blind Multi-center Clinical Trial Evaluating the Efficacy and Safety of Oral QTI571 as an add-on Therapy in the Treatment of Severe Pulmonary Arterial Hypertension: Imatinib in Pulmonary Arterial Hypertension, a Randomized, Efficacy Study (IMPRES)
Status: Enrolling
Updated:  2/16/2016
Novartis Investigative Site
mi
from
Omaha, NE
Imatinib (QTI571) in Pulmonary Arterial Hypertension
A 24-week Randomized Placebo-controlled, Double-blind Multi-center Clinical Trial Evaluating the Efficacy and Safety of Oral QTI571 as an add-on Therapy in the Treatment of Severe Pulmonary Arterial Hypertension: Imatinib in Pulmonary Arterial Hypertension, a Randomized, Efficacy Study (IMPRES)
Status: Enrolling
Updated: 2/16/2016
Novartis Investigative Site
mi
from
Omaha, NE
Click here to add this to my saved trials
Imatinib (QTI571) in Pulmonary Arterial Hypertension
A 24-week Randomized Placebo-controlled, Double-blind Multi-center Clinical Trial Evaluating the Efficacy and Safety of Oral QTI571 as an add-on Therapy in the Treatment of Severe Pulmonary Arterial Hypertension: Imatinib in Pulmonary Arterial Hypertension, a Randomized, Efficacy Study (IMPRES)
Status: Enrolling
Updated:  2/16/2016
Novartis Investigative Site
mi
from
Minneola, NY
Imatinib (QTI571) in Pulmonary Arterial Hypertension
A 24-week Randomized Placebo-controlled, Double-blind Multi-center Clinical Trial Evaluating the Efficacy and Safety of Oral QTI571 as an add-on Therapy in the Treatment of Severe Pulmonary Arterial Hypertension: Imatinib in Pulmonary Arterial Hypertension, a Randomized, Efficacy Study (IMPRES)
Status: Enrolling
Updated: 2/16/2016
Novartis Investigative Site
mi
from
Minneola, NY
Click here to add this to my saved trials
Imatinib (QTI571) in Pulmonary Arterial Hypertension
A 24-week Randomized Placebo-controlled, Double-blind Multi-center Clinical Trial Evaluating the Efficacy and Safety of Oral QTI571 as an add-on Therapy in the Treatment of Severe Pulmonary Arterial Hypertension: Imatinib in Pulmonary Arterial Hypertension, a Randomized, Efficacy Study (IMPRES)
Status: Enrolling
Updated:  2/16/2016
Novartis
mi
from
New York, NY
Imatinib (QTI571) in Pulmonary Arterial Hypertension
A 24-week Randomized Placebo-controlled, Double-blind Multi-center Clinical Trial Evaluating the Efficacy and Safety of Oral QTI571 as an add-on Therapy in the Treatment of Severe Pulmonary Arterial Hypertension: Imatinib in Pulmonary Arterial Hypertension, a Randomized, Efficacy Study (IMPRES)
Status: Enrolling
Updated: 2/16/2016
Novartis
mi
from
New York, NY
Click here to add this to my saved trials
Imatinib (QTI571) in Pulmonary Arterial Hypertension
A 24-week Randomized Placebo-controlled, Double-blind Multi-center Clinical Trial Evaluating the Efficacy and Safety of Oral QTI571 as an add-on Therapy in the Treatment of Severe Pulmonary Arterial Hypertension: Imatinib in Pulmonary Arterial Hypertension, a Randomized, Efficacy Study (IMPRES)
Status: Enrolling
Updated:  2/16/2016
Novartis Investigative Site
mi
from
Durham, NC
Imatinib (QTI571) in Pulmonary Arterial Hypertension
A 24-week Randomized Placebo-controlled, Double-blind Multi-center Clinical Trial Evaluating the Efficacy and Safety of Oral QTI571 as an add-on Therapy in the Treatment of Severe Pulmonary Arterial Hypertension: Imatinib in Pulmonary Arterial Hypertension, a Randomized, Efficacy Study (IMPRES)
Status: Enrolling
Updated: 2/16/2016
Novartis Investigative Site
mi
from
Durham, NC
Click here to add this to my saved trials
Imatinib (QTI571) in Pulmonary Arterial Hypertension
A 24-week Randomized Placebo-controlled, Double-blind Multi-center Clinical Trial Evaluating the Efficacy and Safety of Oral QTI571 as an add-on Therapy in the Treatment of Severe Pulmonary Arterial Hypertension: Imatinib in Pulmonary Arterial Hypertension, a Randomized, Efficacy Study (IMPRES)
Status: Enrolling
Updated:  2/16/2016
Novartis Investigative Site
mi
from
Cincinnati, OH
Imatinib (QTI571) in Pulmonary Arterial Hypertension
A 24-week Randomized Placebo-controlled, Double-blind Multi-center Clinical Trial Evaluating the Efficacy and Safety of Oral QTI571 as an add-on Therapy in the Treatment of Severe Pulmonary Arterial Hypertension: Imatinib in Pulmonary Arterial Hypertension, a Randomized, Efficacy Study (IMPRES)
Status: Enrolling
Updated: 2/16/2016
Novartis Investigative Site
mi
from
Cincinnati, OH
Click here to add this to my saved trials
Imatinib (QTI571) in Pulmonary Arterial Hypertension
A 24-week Randomized Placebo-controlled, Double-blind Multi-center Clinical Trial Evaluating the Efficacy and Safety of Oral QTI571 as an add-on Therapy in the Treatment of Severe Pulmonary Arterial Hypertension: Imatinib in Pulmonary Arterial Hypertension, a Randomized, Efficacy Study (IMPRES)
Status: Enrolling
Updated:  2/16/2016
Novartis Investigative Site
mi
from
Cleveland, OH
Imatinib (QTI571) in Pulmonary Arterial Hypertension
A 24-week Randomized Placebo-controlled, Double-blind Multi-center Clinical Trial Evaluating the Efficacy and Safety of Oral QTI571 as an add-on Therapy in the Treatment of Severe Pulmonary Arterial Hypertension: Imatinib in Pulmonary Arterial Hypertension, a Randomized, Efficacy Study (IMPRES)
Status: Enrolling
Updated: 2/16/2016
Novartis Investigative Site
mi
from
Cleveland, OH
Click here to add this to my saved trials
Imatinib (QTI571) in Pulmonary Arterial Hypertension
A 24-week Randomized Placebo-controlled, Double-blind Multi-center Clinical Trial Evaluating the Efficacy and Safety of Oral QTI571 as an add-on Therapy in the Treatment of Severe Pulmonary Arterial Hypertension: Imatinib in Pulmonary Arterial Hypertension, a Randomized, Efficacy Study (IMPRES)
Status: Enrolling
Updated:  2/16/2016
Novartis Investigative Site
mi
from
Oklahoma City, OK
Imatinib (QTI571) in Pulmonary Arterial Hypertension
A 24-week Randomized Placebo-controlled, Double-blind Multi-center Clinical Trial Evaluating the Efficacy and Safety of Oral QTI571 as an add-on Therapy in the Treatment of Severe Pulmonary Arterial Hypertension: Imatinib in Pulmonary Arterial Hypertension, a Randomized, Efficacy Study (IMPRES)
Status: Enrolling
Updated: 2/16/2016
Novartis Investigative Site
mi
from
Oklahoma City, OK
Click here to add this to my saved trials
Imatinib (QTI571) in Pulmonary Arterial Hypertension
A 24-week Randomized Placebo-controlled, Double-blind Multi-center Clinical Trial Evaluating the Efficacy and Safety of Oral QTI571 as an add-on Therapy in the Treatment of Severe Pulmonary Arterial Hypertension: Imatinib in Pulmonary Arterial Hypertension, a Randomized, Efficacy Study (IMPRES)
Status: Enrolling
Updated:  2/16/2016
Novartis
mi
from
Portland, OR
Imatinib (QTI571) in Pulmonary Arterial Hypertension
A 24-week Randomized Placebo-controlled, Double-blind Multi-center Clinical Trial Evaluating the Efficacy and Safety of Oral QTI571 as an add-on Therapy in the Treatment of Severe Pulmonary Arterial Hypertension: Imatinib in Pulmonary Arterial Hypertension, a Randomized, Efficacy Study (IMPRES)
Status: Enrolling
Updated: 2/16/2016
Novartis
mi
from
Portland, OR
Click here to add this to my saved trials
Imatinib (QTI571) in Pulmonary Arterial Hypertension
A 24-week Randomized Placebo-controlled, Double-blind Multi-center Clinical Trial Evaluating the Efficacy and Safety of Oral QTI571 as an add-on Therapy in the Treatment of Severe Pulmonary Arterial Hypertension: Imatinib in Pulmonary Arterial Hypertension, a Randomized, Efficacy Study (IMPRES)
Status: Enrolling
Updated:  2/16/2016
Novartis Investigative Site
mi
from
Philadelphia, PA
Imatinib (QTI571) in Pulmonary Arterial Hypertension
A 24-week Randomized Placebo-controlled, Double-blind Multi-center Clinical Trial Evaluating the Efficacy and Safety of Oral QTI571 as an add-on Therapy in the Treatment of Severe Pulmonary Arterial Hypertension: Imatinib in Pulmonary Arterial Hypertension, a Randomized, Efficacy Study (IMPRES)
Status: Enrolling
Updated: 2/16/2016
Novartis Investigative Site
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Imatinib (QTI571) in Pulmonary Arterial Hypertension
A 24-week Randomized Placebo-controlled, Double-blind Multi-center Clinical Trial Evaluating the Efficacy and Safety of Oral QTI571 as an add-on Therapy in the Treatment of Severe Pulmonary Arterial Hypertension: Imatinib in Pulmonary Arterial Hypertension, a Randomized, Efficacy Study (IMPRES)
Status: Enrolling
Updated:  2/16/2016
Novartis
mi
from
Pittsburgh, PA
Imatinib (QTI571) in Pulmonary Arterial Hypertension
A 24-week Randomized Placebo-controlled, Double-blind Multi-center Clinical Trial Evaluating the Efficacy and Safety of Oral QTI571 as an add-on Therapy in the Treatment of Severe Pulmonary Arterial Hypertension: Imatinib in Pulmonary Arterial Hypertension, a Randomized, Efficacy Study (IMPRES)
Status: Enrolling
Updated: 2/16/2016
Novartis
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Imatinib (QTI571) in Pulmonary Arterial Hypertension
A 24-week Randomized Placebo-controlled, Double-blind Multi-center Clinical Trial Evaluating the Efficacy and Safety of Oral QTI571 as an add-on Therapy in the Treatment of Severe Pulmonary Arterial Hypertension: Imatinib in Pulmonary Arterial Hypertension, a Randomized, Efficacy Study (IMPRES)
Status: Enrolling
Updated:  2/16/2016
Novartis Investigative Site
mi
from
Knoxville, TN
Imatinib (QTI571) in Pulmonary Arterial Hypertension
A 24-week Randomized Placebo-controlled, Double-blind Multi-center Clinical Trial Evaluating the Efficacy and Safety of Oral QTI571 as an add-on Therapy in the Treatment of Severe Pulmonary Arterial Hypertension: Imatinib in Pulmonary Arterial Hypertension, a Randomized, Efficacy Study (IMPRES)
Status: Enrolling
Updated: 2/16/2016
Novartis Investigative Site
mi
from
Knoxville, TN
Click here to add this to my saved trials
Imatinib (QTI571) in Pulmonary Arterial Hypertension
A 24-week Randomized Placebo-controlled, Double-blind Multi-center Clinical Trial Evaluating the Efficacy and Safety of Oral QTI571 as an add-on Therapy in the Treatment of Severe Pulmonary Arterial Hypertension: Imatinib in Pulmonary Arterial Hypertension, a Randomized, Efficacy Study (IMPRES)
Status: Enrolling
Updated:  2/16/2016
Novartis Investigative site
mi
from
Dallas, TX
Imatinib (QTI571) in Pulmonary Arterial Hypertension
A 24-week Randomized Placebo-controlled, Double-blind Multi-center Clinical Trial Evaluating the Efficacy and Safety of Oral QTI571 as an add-on Therapy in the Treatment of Severe Pulmonary Arterial Hypertension: Imatinib in Pulmonary Arterial Hypertension, a Randomized, Efficacy Study (IMPRES)
Status: Enrolling
Updated: 2/16/2016
Novartis Investigative site
mi
from
Dallas, TX
Click here to add this to my saved trials
Imatinib (QTI571) in Pulmonary Arterial Hypertension
A 24-week Randomized Placebo-controlled, Double-blind Multi-center Clinical Trial Evaluating the Efficacy and Safety of Oral QTI571 as an add-on Therapy in the Treatment of Severe Pulmonary Arterial Hypertension: Imatinib in Pulmonary Arterial Hypertension, a Randomized, Efficacy Study (IMPRES)
Status: Enrolling
Updated:  2/16/2016
Novartis Investigative Site
mi
from
Houston, TX
Imatinib (QTI571) in Pulmonary Arterial Hypertension
A 24-week Randomized Placebo-controlled, Double-blind Multi-center Clinical Trial Evaluating the Efficacy and Safety of Oral QTI571 as an add-on Therapy in the Treatment of Severe Pulmonary Arterial Hypertension: Imatinib in Pulmonary Arterial Hypertension, a Randomized, Efficacy Study (IMPRES)
Status: Enrolling
Updated: 2/16/2016
Novartis Investigative Site
mi
from
Houston, TX
Click here to add this to my saved trials